There are currently 546 clinical trials in Madison, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Wisconsin, University of Wisconsin Hospital and Clinics, University of Wisconsin Carbone Cancer Center and University of Wisconsin - Madison. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
NCT04973605
Recruiting
Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277
Recruiting
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Uni Wisconsin School Med Pub Health Clinical Research Office, Madison, Wisconsin
Conditions: Lupus Nephritis
Register for Updates
A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors
NCT05318573
Recruiting
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Wisconsin Clinical Science Center, Madison, Wisconsin
Conditions: Advanced Solid Tumor
Register for Updates
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
NCT05589714
Recruiting
This is an international, multicenter study with two components: Registry A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection Enrollment is open to all genes on the RD Rare Gene List Natural History Study A prospective, standardized, longitudinal Natural History Study Enrollment opens gene-by-gene, based on funding and within-gene Registry enrollment The study objectives are as follows. Registry Objectives Genotype Characterization Cro... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
04/24/2024
Locations: University of Wisconsin Madison, Madison, Wisconsin
Conditions: Inherited Retinal Degeneration, Retinitis Pigmentosa
Register for Updates
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741
Recruiting
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/24/2024
Locations: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Conditions: Cystic Fibrosis
Register for Updates
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05554328
Recruiting
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
Register for Updates
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
NCT04116437
Recruiting
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Ssm Health Cancer Care Dean Medical Center, Madison, Wisconsin
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Register for Updates
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04166409
Recruiting
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs... Read More
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
04/24/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Low Grade Glioma, Low Grade Astrocytoma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma
Register for Updates
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211
Recruiting
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
04/24/2024
Locations: Research Site, Madison, Wisconsin
Conditions: Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
Register for Updates
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
NCT05372614
Recruiting
This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread to other parts of the body (metastatic) or that cannot be removed by surgery (unresectable), and have changes in a gene called human epidermal growth factor receptor 2 (HER2). Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Malignant Solid Neoplasm
Register for Updates
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559
Recruiting
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent centra... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University Hospital and UW Health Clinics ( Site 0006), Madison, Wisconsin
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)
NCT05947851
Recruiting
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423), Madison, Wisconsin
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
Register for Updates